RT Journal Article
T1 Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
A1 Fernandez-Martinez, Aranzazu
A1 Pascual, Tomás
A1 Perrone, Giuseppe
A1 Morales, Serafin
A1 de la Haba, Juan
A1 González-Rivera, Milagros
A1 Galván, Patricia
A1 Zalfa, Francesca
A1 Amato, Michela
A1 Gonzalez, Lucia
A1 Prats, Miquel
A1 Rojo, Federico
A1 Manso, Luis
A1 Paré, Laia
A1 Alonso, Immaculada
A1 Albanell, Joan
A1 Vivancos, Ana
A1 González, Antonio
A1 Matito, Judit
A1 González, Sonia
A1 Fernandez, Pedro
A1 Adamo, Barbara
A1 Muñoz, Montserrat
A1 Viladot, Margarita
A1 Font, Carme
A1 Aya, Francisco
A1 Vidal, Maria
A1 Caballero, Rosalía
A1 Carrasco, Eva
A1 Altomare, Vittorio
A1 Tonini, Giuseppe
A1 Prat, Aleix
A1 Martin, Miguel
K1 Ki67
K1 PAM50/Prosigna
K1 breast cancer
K1 estrogen receptor-positive/HER2-negative
AB PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.
YR 2017
FD 2017
LK https://hdl.handle.net/10668/25130
UL https://hdl.handle.net/10668/25130
LA en
DS RISalud
RD Apr 6, 2025